Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on November 10, 2009
JNCI Journal of the National Cancer Institute 2009 101(22):1527-1529; doi:10.1093/jnci/djp376
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/22/1527    most recent
djp376v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kim, E.
Right arrow Articles by Shohet, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, E.
Right arrow Articles by Shohet, J.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press.

EDITORIALS

Targeted Molecular Therapy for Neuroblastoma: The ARF/MDM2/p53 Axis

Eugene Kim, Jason Shohet

Affiliations of authors: Micheal E. Debakey Department of Surgery (EK) and Department of Pediatrics (JS), Baylor College of Medicine, Houston, TX

Correspondence to: Jason Shohet, MD, PhD, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Feigin Building, Room 750.01, 1102 Bates St, Houston, TX 77030 (e-mail: jmshohet@texaschildrenshospital.org).

The first 150 words of the full text of this article appear below.

Neuroblastoma remains a major therapeutic challenge in pediatric oncology despite decades of intensive research and therapeutic trials. This aggressive embryonal malignancy of neural crest origin has a peak age of onset of 22 months and accounts for approximately 11% of all pediatric cancers and 15% of all pediatric cancer deaths (1). With current treatment protocols, including high-dose chemotherapy with autologous stem cell transplantation, radiation, and surgery, about 80% of high-risk patients will go into remission (2). However, the majority of these patients relapse and succumb to therapy-resistant tumors and have long-term survival rates of less than 50%. As illustrated by the work presented by Van Maerken et al. (3), studies using both cell culture and animal models of neuroblastoma are producing exciting new discoveries into its pathogenesis and molecular biology. These insights provide hope that rationally designed and targeted molecular therapeutics can be translated . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2009 101: 1523. [Extract] [Full Text] [PDF]